GET DAILY SIGNALSCanopy Growth (CGC) Reports +22% Revenue Growth in Q2 FY2027
Key Takeaways
- Consolidated net revenue rose 22% year over year to C$81.4 million, but came in modestly below analyst consensus estimates.
- International markets cannabis net revenue surged 141% to C$12.3 million, driven by strong European sales in Germany and Poland.
- Canada Medical revenue climbed 18% to C$25.8 million, while Canada Adult Use revenue increased 17% to C$28.1 million.
- Storz & Bickel revenue slipped 4% to C$15.1 million on softer consumer spending.
- Adjusted EBITDA loss narrowed to C$2.9 million.
- Net loss widened year over year, weighed down by C$35.8 million in fair-value charges tied to Canopy USA assets.
Earnings Context and Why It Matters
Canopy Growth reported its second quarter fiscal 2027 results, covering the three months ended September 30, 2026, on November 6, 2026. The report matters because it offers the clearest test yet of whether the company can convert its international expansion and cost discipline into a sustainable path toward profitability. Over the prior fiscal year, Canopy reset its business, completed the acquisition of MTL Cannabis, and moved to a net cash position. Investors are closely watching whether rising overseas cannabis sales and the integration of MTL can offset headwinds from the Veterans Affairs Canada reimbursement reduction and softening demand in the company's vaporizer segment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Canopy Growth posted consolidated net revenue of C$81.4 million for Q2 FY2027, a 22% increase year over year, but slightly below analyst expectations. Cannabis net revenue grew 30% to C$66.2 million, with the international markets cannabis segment the standout, rising 141% to C$12.3 million on strong demand in Germany and Poland. From what I see, the international momentum stands out as a key positive. Within Canada, medical cannabis revenue increased 18% to C$25.8 million, while adult-use cannabis revenue rose 17% to C$28.1 million. The Storz & Bickel vaporizer segment declined 4% to C$15.1 million amid softer consumer spending. Adjusted gross margin came in at 31%, down from 33% a year earlier, partly reflecting the Veterans Affairs Canada reimbursement-rate reduction.
The adjusted EBITDA loss improved to C$2.9 million, narrowing sequentially from the prior quarter. However, net loss widened by roughly C$35.7 million year over year, largely due to C$35.8 million in fair-value charges related to Canopy USA assets. The company ended the quarter with C$320 million in cash and short-term investments, and management reaffirmed its expectation of reaching positive adjusted EBITDA during fiscal 2027. I’m watching this closely as the cash position provides important flexibility.
Market Reaction and Investor Sentiment
Shares of CGC traded lower on Friday following the report, as investors weighed the revenue miss and the wider net loss against the company's accelerating international momentum. The top-line shortfall against consensus, combined with the C$35.8 million fair-value charges tied to Canopy USA assets, appeared to temper enthusiasm even as the underlying cannabis business delivered solid double-digit growth. Investor sentiment around Canopy remains centered on the credibility of its profitability timeline, with the narrowing adjusted EBITDA loss providing a modest positive signal that cost controls and integration synergies are beginning to flow through the income statement.
Forward Outlook and Key Factors to Monitor
Looking ahead, Canopy Growth has signaled that year-over-year improvements should be more pronounced in the second half of fiscal 2027, supported by seasonality in the Storz & Bickel business and the continued flow-through of cost savings. Management has reiterated its line of sight to positive adjusted EBITDA during the fiscal year, a milestone investors will be tracking closely in the coming quarters.
Several factors will shape the path forward. First, cultivation improvements at the Kincardine facility are expected to drive higher yield and flower quality, with a noticeable impact beginning as the company exits the third quarter. Second, recently obtained EU GMP certifications at both Smiths Falls and Kincardine could broaden Canopy's product offering in Europe beyond flower, expanding its addressable market.
Investors should also monitor the ongoing impact of the Veterans Affairs Canada reimbursement reduction on the Canadian medical segment, as well as demand trends in the Storz & Bickel segment, which has faced softer consumer spending. Finally, Canopy's strong cash position gives it flexibility for selective M&A or other strategic opportunities, while a potential share consolidation remains available if needed to maintain its Nasdaq listing.
Leveraging AI Tools in My Analysis
In my research process, I often turn to Tickeron’s AI-powered tools to quickly scan for comparable setups and validate trends across the sector. The AI Screener stands out for its ability to filter stocks by patterns, fundamentals, and performance metrics, helping surface ideas that align with the factors I’m tracking here. It has become a regular part of how I cross-check earnings momentum and peer comparisons without spending hours on manual work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CGC in +10.41% Uptrend, rising for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CGC advanced for three days, in 162 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CGC's RSI Oscillator exited the oversold zone, 35 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 75 cases where CGC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for CGC just turned positive on November 02, 2026. Looking at past instances where CGC's MACD turned positive, the stock continued to rise in 31 of 40 cases over the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CGC as a result. In 78 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CGC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CGC entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. CGC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.400) is normal, around the industry mean (7.254). P/E Ratio (-0.972) is within average values for comparable stocks, (0.575). CGC's Projected Growth (PEG Ratio) (7.200) is slightly higher than the industry average of (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (1.549) is also within normal values, averaging (181.047).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of medical marijuana
Industry PharmaceuticalsGeneric
Advertisement